BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22516689)

  • 1. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance.
    Venturini L; Daidone MG; Motta R; Cimino-Reale G; Hoare SF; Gronchi A; Folini M; Keith WN; Zaffaroni N
    Neuro Oncol; 2012 Jun; 14(6):736-44. PubMed ID: 22516689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.
    Venturini L; Daidone MG; Motta R; Collini P; Spreafico F; Terenziani M; Piva L; Radice P; Perotti D; Zaffaroni N
    Genes Chromosomes Cancer; 2011 Oct; 50(10):823-9. PubMed ID: 21769957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.
    Villa R; Daidone MG; Motta R; Venturini L; De Marco C; Vannelli A; Kusamura S; Baratti D; Deraco M; Costa A; Reddel RR; Zaffaroni N
    Clin Cancer Res; 2008 Jul; 14(13):4134-40. PubMed ID: 18593991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression.
    Costa A; Daidone MG; Daprai L; Villa R; Cantù S; Pilotti S; Mariani L; Gronchi A; Henson JD; Reddel RR; Zaffaroni N
    Cancer Res; 2006 Sep; 66(17):8918-24. PubMed ID: 16951210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomere alterations in neurofibromatosis type 1-associated solid tumors.
    Rodriguez FJ; Graham MK; Brosnan-Cashman JA; Barber JR; Davis C; Vizcaino MA; Palsgrove DN; Giannini C; Pekmezci M; Dahiya S; Gokden M; Noë M; Wood LD; Pratilas CA; Morris CD; Belzberg A; Blakeley J; Heaphy CM
    Acta Neuropathol Commun; 2019 Aug; 7(1):139. PubMed ID: 31462295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals.
    Mantripragada KK; Caley M; Stephens P; Jones CJ; Kluwe L; Guha A; Mautner V; Upadhyaya M
    Genes Chromosomes Cancer; 2008 Mar; 47(3):238-46. PubMed ID: 18069666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas.
    Matsuo T; Shay JW; Wright WE; Hiyama E; Shimose S; Kubo T; Sugita T; Yasunaga Y; Ochi M
    J Bone Joint Surg Am; 2009 Apr; 91(4):928-37. PubMed ID: 19339578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
    LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
    Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST.
    Miao R; Wang H; Jacobson A; Lietz AP; Choy E; Raskin KA; Schwab JH; Deshpande V; Nielsen GP; DeLaney TF; Cote GM; Hornicek FJ; Chen YE
    Radiother Oncol; 2019 Aug; 137():61-70. PubMed ID: 31078939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.
    Lamm W; Schur S; Köstler WJ; Funovics P; Windhager R; Amann G; Panotopoulos J; Pokrajac B; Brodowicz T
    Oncology; 2014; 86(2):122-6. PubMed ID: 24480823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
    Kolberg M; Høland M; Agesen TH; Brekke HR; Liestøl K; Hall KS; Mertens F; Picci P; Smeland S; Lothe RA
    Neuro Oncol; 2013 Feb; 15(2):135-47. PubMed ID: 23161774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location.
    Kamran SC; Howard SA; Shinagare AB; Krajewski KM; Jagannathan JP; Hornick JL; Ramaiya NH
    Eur J Surg Oncol; 2013 Jan; 39(1):46-52. PubMed ID: 23084090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma.
    Else T; Giordano TJ; Hammer GD
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1442-9. PubMed ID: 18198226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma.
    Ulaner GA; Huang HY; Otero J; Zhao Z; Ben-Porat L; Satagopan JM; Gorlick R; Meyers P; Healey JH; Huvos AG; Hoffman AR; Ladanyi M
    Cancer Res; 2003 Apr; 63(8):1759-63. PubMed ID: 12702558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
    Grobelny JV; Kulp-McEliece M; Broccoli D
    Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation, TERT promoter mutation, and HER2 amplification in sporadic or neurofibromatosis-related neurofibromas and malignant peripheral nerve sheath tumors: do these molecules have a signature in malignant transformation?
    Coskun S; Gamsizkan M; Yilmaz I; Yalcinkaya U; Sungur MA; Buyucek S; Onal B
    APMIS; 2020 Sep; 128(9):515-522. PubMed ID: 32580246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
    Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
    Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomere maintenance by telomerase and by recombination can coexist in human cells.
    Cerone MA; Londono-Vallejo JA; Bacchetti S
    Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
    Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR
    Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.